Amphastar Pharmaceuticals Gross Margin 2012-2024 | AMPH
Current and historical gross margin for Amphastar Pharmaceuticals (AMPH) over the last 10 years. The current gross profit margin for Amphastar Pharmaceuticals as of September 30, 2024 is %.
| Amphastar Pharmaceuticals Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2024-09-30 |
$0.72B |
$0.38B |
52.97% |
| 2024-06-30 |
$0.71B |
$0.39B |
54.56% |
| 2024-03-31 |
$0.68B |
$0.37B |
54.21% |
| 2023-12-31 |
$0.65B |
$0.35B |
54.42% |
| 2023-09-30 |
$0.60B |
$0.33B |
54.15% |
| 2023-06-30 |
$0.54B |
$0.28B |
51.20% |
| 2023-03-31 |
$0.52B |
$0.27B |
51.54% |
| 2022-12-31 |
$0.50B |
$0.25B |
50.00% |
| 2022-09-30 |
$0.48B |
$0.23B |
48.35% |
| 2022-06-30 |
$0.48B |
$0.23B |
47.48% |
| 2022-03-31 |
$0.46B |
$0.21B |
46.15% |
| 2021-12-31 |
$0.44B |
$0.20B |
45.43% |
| 2021-09-30 |
$0.41B |
$0.18B |
43.58% |
| 2021-06-30 |
$0.38B |
$0.17B |
43.23% |
| 2021-03-31 |
$0.37B |
$0.15B |
41.30% |
| 2020-12-31 |
$0.35B |
$0.14B |
41.14% |
| 2020-09-30 |
$0.34B |
$0.14B |
41.54% |
| 2020-06-30 |
$0.33B |
$0.14B |
41.32% |
| 2020-03-31 |
$0.33B |
$0.14B |
41.90% |
| 2019-12-31 |
$0.32B |
$0.13B |
40.68% |
| 2019-09-30 |
$0.33B |
$0.13B |
40.43% |
| 2019-06-30 |
$0.33B |
$0.13B |
39.08% |
| 2019-03-31 |
$0.32B |
$0.12B |
38.17% |
| 2018-12-31 |
$0.30B |
$0.11B |
36.27% |
| 2018-09-30 |
$0.27B |
$0.09B |
34.72% |
| 2018-06-30 |
$0.25B |
$0.08B |
34.01% |
| 2018-03-31 |
$0.24B |
$0.09B |
35.27% |
| 2017-12-31 |
$0.24B |
$0.09B |
37.92% |
| 2017-09-30 |
$0.24B |
$0.09B |
37.30% |
| 2017-06-30 |
$0.25B |
$0.10B |
39.20% |
| 2017-03-31 |
$0.25B |
$0.10B |
40.71% |
| 2016-12-31 |
$0.26B |
$0.11B |
41.18% |
| 2016-09-30 |
$0.27B |
$0.12B |
44.03% |
| 2016-06-30 |
$0.27B |
$0.11B |
40.30% |
| 2016-03-31 |
$0.25B |
$0.09B |
35.04% |
| 2015-12-31 |
$0.25B |
$0.08B |
30.56% |
| 2015-09-30 |
$0.23B |
$0.06B |
24.24% |
| 2015-06-30 |
$0.23B |
$0.05B |
22.03% |
| 2015-03-31 |
$0.22B |
$0.05B |
23.42% |
| 2014-12-31 |
$0.21B |
$0.05B |
24.64% |
| 2014-09-30 |
$0.21B |
$0.06B |
28.57% |
| 2014-06-30 |
$0.21B |
$0.07B |
32.54% |
| 2014-03-31 |
$0.22B |
$0.08B |
35.87% |
| 2013-12-31 |
$0.23B |
$0.09B |
37.83% |
| 2013-09-30 |
$0.23B |
$0.12B |
52.42% |
| 2013-06-30 |
$0.23B |
$0.16B |
69.33% |
| 2013-03-31 |
$0.21B |
$0.18B |
84.36% |
| 2012-12-31 |
$0.20B |
$0.20B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.894B |
$0.644B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
